| Patient | Mary McLeod Bethune |
|---|---|
| Date of birth | 1875-07-10 |
| Identifiers | MRN HR-ML043-SYN-TD; SSN (made up) 000-43-2195 |
| Document date | 2026-11-01 |
| Author | Viola Harrington-Mbeki, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for four months of wheeze, night cough and breathlessness on exertion in a 72-year-old woman with long-standing asthma that was never confirmed: examination, chest X-ray, ECG, blood tests and BNP, and planning of lung function testing and an echocardiogram. Concerns: Her breathing wakes her at night and stops her climbing stairs, and she has had to travel less; She has been told for years that it is asthma, or her weight, or her heart, and wants to know for certain which it is; She wants to keep going to Washington for the council's meetings. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two puffs as needed, from an urgent care visit four months ago (used alone, without an inhaled steroid) | Two puffs every 4 hours as needed; she uses it most days | Respiratory tract route | 1947-11-03 to 1948-03-23 | completed | S |
| Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for five days | 40 mg each morning for five days | Oral route | 1948-06-15 to 1948-06-19 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day | One inhalation twice daily plus one as needed | Respiratory tract route | 1948-03-23 to 1948-06-15 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: two inhalations twice daily and one as needed (stepped up during the exacerbation), no more than 12 inhalations a day | Two inhalations twice daily plus one as needed | Respiratory tract route | 1948-06-15 to 1948-07-27 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: one inhalation twice daily and one as needed, no more than 12 inhalations a day | One inhalation twice daily plus one as needed | Respiratory tract route | 1948-07-27 | active | S |
| Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septum | Two sprays each nostril daily | Nasal route | 1948-03-23 | active | S |
| Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid spray | Two sprays each nostril up to four times daily | Nasal route | 1948-03-23 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1948-03-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1948-03-23 | active | S |
| Omeprazole 20 mg delayed-release capsule, one capsule daily 30 minutes before breakfast for eight weeks | One capsule daily before breakfast | Oral route | 1948-03-23 to 1948-05-18 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Chest X-ray, posteroanterior and lateral: mild hyperinflation; heart size normal (cardiothoracic ratio 0.48); no pulmonary edema, effusion, mass or consolidation | 1948-03-09 to 1948-03-09 | completed | S |
| Resting 12-lead ECG: sinus rhythm at 80 per minute; left ventricular hypertrophy by voltage criteria; no Q waves, ST changes or arrhythmia | 1948-03-09 to 1948-03-09 | completed | S |
| Advance care planning conversation, about 25 minutes, with her consent | 1948-09-21 to 1948-09-21 | completed | S |
| Spirometry before and 15 minutes after albuterol 400 mcg, with DLCO and FeNO, interpreted with GLI Global race-neutral equations: FEV1 1.30 L (64 percent predicted) rising to 1.57 L (+270 mL, +21 percent); FEV1/FVC 0.64 before and 0.72 after; DLCO 92 percent predicted; FeNO 46 ppb. Variable airflow obstruction without persistent obstruction: asthma, not COPD | 1948-03-23 to 1948-03-23 | completed | S |
| Transthoracic echocardiogram: left ventricular ejection fraction 62 percent; mild concentric left ventricular hypertrophy (septum 1.2 cm); grade 1 diastolic dysfunction; left atrium normal in size; right ventricle normal; estimated pulmonary artery systolic pressure 28 mmHg; no significant valve disease | 1948-03-23 to 1948-03-23 | completed | S |
| Written asthma action plan with peak flow zones (green above 270 L/min, yellow 170 to 270, red below 170, based on a provisional best of 340 to be confirmed), given and explained | 1948-03-23 to 1948-03-23 | completed | S |
| Nasal endoscopy by the ear, nose and throat specialist: swollen mucosa and mucus in both middle meatuses; no polyps or mass; septum near midline | 1948-04-20 to 1948-04-20 | completed | S |
| Inhaler technique assessment with her own inhaler: she did not shake it, breathed in fast and did not hold her breath; retrained with a spacer and checked by teach-back | 1948-05-04 to 1948-05-04 | completed | S |
| Spirometry before bronchodilator after stabilization: FEV1 1.72 L (85 percent predicted); FEV1/FVC 0.73 | 1948-07-27 to 1948-07-27 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1946-05-14 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
| 1943-02-08 | Tdap vaccine | completed | S |
| 1948-03-23 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 1948-09-21 | Influenza vaccine, high-dose, this season | completed | S |
| 1948-09-21 | COVID-19 mRNA vaccine, this season's formula | completed | S |
| 1948-09-21 | Respiratory syncytial virus vaccine, single dose | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1942 | Chronic asthma for many years, increasingly limiting her travel; a particularly severe attack in 1942, after which she gave up the presidency of the college | D (CLM-0005) |
| 1943 | Repeated asthma attacks recorded in her correspondence | D (CLM-0006) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Her breathing wakes her at night and stops her climbing stairs, and she has had to travel less | active | S |
| She has been told for years that it is asthma, or her weight, or her heart, and wants to know for certain which it is | active | S |
| She wants to keep going to Washington for the council's meetings | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 13 on 1948-07-27; Leukocytes [#/volume] in Blood by Automated count 7.1 on 1948-07-27; Eosinophils [#/volume] in Blood by Automated count 0.24 on 1948-07-27; Platelets [#/volume] in Blood by Automated count 255 on 1948-07-27; Sodium [Moles/volume] in Serum or Plasma 140 on 1948-03-09; Potassium [Moles/volume] in Serum or Plasma 4.3 on 1948-07-27; Creatinine [Mass/volume] in Serum or Plasma 0.96 on 1948-07-27; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1943)/1.73 sq M 62 on 1948-07-27; Glucose [Mass/volume] in Serum or Plasma 102 on 1948-03-09; Hemoglobin A1c/Hemoglobin.total in Blood 5.9 on 1948-03-09; Thyrotropin [Units/volume] in Serum or Plasma 2.2 on 1948-03-09; Natriuretic peptide B [Mass/volume] in Serum or Plasma 48 on 1948-03-09; Cholesterol [Mass/volume] in Serum or Plasma 170 on 1948-05-04; Cholesterol in HDL [Mass/volume] in Serum or Plasma 57 on 1948-05-04; Triglyceride [Mass/volume] in Serum or Plasma 126 on 1948-05-04; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 88 on 1948-05-04; Albumin/Creatinine [Mass Ratio] in Urine 18 on 1948-03-09; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1948-07-27; Total score [ACT] 22 on 1948-07-27; Maximum expiratory gas flow Respiratory system airway by Peak flow meter 330 on 1948-07-27; Total score [Mini-Cog] 5 on 1948-09-21; Total score [AUDIT-C] 0 on 1948-09-21; FEV1 --pre bronchodilation 1.72 on 1948-07-27; FEV1 --post bronchodilation 1.57 on 1948-03-23; FEV1 measured/predicted 85 on 1948-07-27; FEV1/FVC 0.73 on 1948-07-27; FEV1/FVC --post bronchodilation 0.72 on 1948-03-23; Diffusion capacity.carbon monoxide 17.2 on 1948-03-23; Fractional concentration of exhaled nitric oxide 21 on 1948-07-27; Left ventricular Ejection fraction 62 on 1948-03-23; IgE [Units/volume] in Serum or Plasma 210 on 1948-03-23 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Wheeze, cough and breathlessness for four months: waking with cough and tight chest two or three nights a week, breathless on one flight of stairs, relieved by albuterol, worse with colds, dust and strong scents; known asthma for many years but never confirmed by lung function testing and never treated with an inhaled steroid. Asthma, COPD and heart failure to be distinguished: spirometry with bronchodilator response, FeNO and an echocardiogram booked | resolved | confirmed | R06.2 | S — Synthetic presenting problem anchored to her documented chronic asthma. Superseded by the diagnosis at the second visit. |
| Blocked nose, thick postnasal drip and a reduced sense of smell for years, worse in the last year; no nosebleeds; never seen by an ear, nose and throat specialist | resolved | confirmed | R09.81 | S — Synthetic upper-airway symptoms; superseded by the diagnosis of chronic rhinosinusitis after nasal endoscopy. |
| Gastro-esophageal reflux: heartburn and an acid taste two or three evenings a week, worse after late meals and lying down; no trouble swallowing, vomiting, black stools or weight loss | active | confirmed | K21.9 | S — Synthetic comorbidity of asthma; not a claim about her real health. |
| Obesity, class 1 (BMI 33.1); she wants to walk more and to keep up with her work, and agreed to talk about it | active | confirmed | E66.811 | S — Synthetic comorbidity recorded in her words and with her agreement; not a claim about her real weight. |
| Moderate asthma exacerbation triggered by a cold: two days of worsening wheeze and night waking despite eight reliever inhalations a day, peak flow 205 L/min (60 percent of her best), oxygen saturation 94 percent; improved to 275 L/min in clinic; treated without admission; resolved | resolved | confirmed | J45.41 | S — Synthetic exacerbation; not a claim about a real attack. |
| Asthma, confirmed: variable airflow obstruction (FEV1 64 percent predicted, rising 270 mL or 21 percent after bronchodilator, with a normal post-bronchodilator FEV1/FVC of 0.72 and normal DLCO); type 2 inflammation (FeNO 46 ppb, blood eosinophils 0.42 x10^3/uL, total IgE 210, house dust mite sensitization); not COPD and not heart failure. Uncontrolled at diagnosis on albuterol alone | active | confirmed | J45.40 | S — Synthetic modern confirmation linked to her documented chronic asthma. |
| Hypertensive heart disease without heart failure: clinic blood pressure 152/88 and 146/86, home average 144/84; mild concentric left ventricular hypertrophy with grade 1 diastolic dysfunction and a normal ejection fraction (62 percent); BNP 48 pg/mL | active | confirmed | I11.9 | S — Synthetic finding of the modern work-up; not a claim about her real heart. |
| Hyperlipidemia: LDL cholesterol 144 mg/dL; 10-year ASCVD risk above 20 percent with hypertension | active | confirmed | E78.5 | S — Synthetic cardiovascular risk factor. |
| Chronic rhinosinusitis without nasal polyps: years of congestion, postnasal drip and reduced smell, with mucosal swelling and mucus in both middle meatuses and no polyps on nasal endoscopy | active | confirmed | J32.9 | S — Synthetic upper-airway comorbidity of asthma; not a claim about her real health. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1948-03-09 | Hemoglobin [Mass/volume] in Blood | 12.9 | g/dL | 12-15.5 g/dL | Normal | S |
| 1948-03-09 | Leukocytes [#/volume] in Blood by Automated count | 7.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1948-03-09 | Eosinophils [#/volume] in Blood by Automated count | 0.42 | 10*3/uL | 0-0.5 10*3/uL | Normal | S |
| 1948-03-09 | Platelets [#/volume] in Blood by Automated count | 268 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1948-03-09 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1948-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1948-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1948-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1943)/1.73 sq M | 66 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1948-03-09 | Glucose [Mass/volume] in Serum or Plasma | 102 | mg/dL | 70-99 mg/dL | High | S |
| 1948-03-09 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.9 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes | High | S |
| 1948-03-09 | Thyrotropin [Units/volume] in Serum or Plasma | 2.2 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1948-03-09 | Natriuretic peptide B [Mass/volume] in Serum or Plasma | 48 | pg/mL | Below 100 pg/mL makes heart failure unlikely | Normal | S |
| 1948-03-09 | Cholesterol [Mass/volume] in Serum or Plasma | 228 | mg/dL | <=199 mg/dL | High | S |
| 1948-03-09 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 56 | mg/dL | 50 mg/dL or more for women | Normal | S |
| 1948-03-09 | Triglyceride [Mass/volume] in Serum or Plasma | 140 | mg/dL | <=149 mg/dL | Normal | S |
| 1948-03-09 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 144 | mg/dL | <=99 mg/dL | High | S |
| 1948-03-09 | Albumin/Creatinine [Mass Ratio] in Urine | 18 | mg/g | <=30 mg/g | Normal | S |
| 1948-03-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1948-03-09 | Total score [ACT] | 13 | {score} | S | ||
| 1948-06-15 | Maximum expiratory gas flow Respiratory system airway by Peak flow meter | 205 | L/min | 80 percent of her personal best of 340 L/min | Low | S |
| 1948-09-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1948-09-21 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 1948-09-21 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 1948-03-23 | FEV1 --pre bronchodilation | 1.3 | L | Lower limit of normal, GLI Global race-neutral equations; predicted 2.03 L | Low | S |
| 1948-03-23 | FEV1 --post bronchodilation | 1.57 | L | Lower limit of normal, GLI Global race-neutral equations; predicted 2.03 L | Normal | S |
| 1948-03-23 | FEV1 measured/predicted | 64 | % | GLI Global race-neutral equations | Low | S |
| 1948-03-23 | FEV1/FVC | 0.64 | {ratio} | >=0.7 | Low | S |
| 1948-03-23 | FEV1/FVC --post bronchodilation | 0.72 | {ratio} | 0.70 or more after bronchodilator: no persistent airflow obstruction | Normal | S |
| 1948-03-23 | Diffusion capacity.carbon monoxide | 17.2 | mL/min/mm[Hg] | Lower limit of normal, GLI race-neutral; predicted 18.6 | Normal | S |
| 1948-03-23 | Fractional concentration of exhaled nitric oxide | 46 | [ppb] | Above 50 ppb high; 25 to 50 intermediate (ATS) | High | S |
| 1948-03-23 | Left ventricular Ejection fraction | 62 | % | 53-73% | Normal | S |
| 1948-03-23 | IgE [Units/volume] in Serum or Plasma | 210 | [IU]/mL | <=100 [IU]/mL | High | S |
| 1948-03-23 | Total score [ACT] | 14 | {score} | S | ||
| 1948-05-04 | Total score [ACT] | 18 | {score} | S | ||
| 1948-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1948-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1948-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1943)/1.73 sq M | 64 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1948-05-04 | Cholesterol [Mass/volume] in Serum or Plasma | 170 | mg/dL | <=199 mg/dL | Normal | S |
| 1948-05-04 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 57 | mg/dL | 50 mg/dL or more for women | Normal | S |
| 1948-05-04 | Triglyceride [Mass/volume] in Serum or Plasma | 126 | mg/dL | <=149 mg/dL | Normal | S |
| 1948-05-04 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 88 | mg/dL | <=99 mg/dL | Normal | S |
| 1948-07-27 | Total score [ACT] | 22 | {score} | S | ||
| 1948-07-27 | FEV1 --pre bronchodilation | 1.72 | L | Lower limit of normal, GLI Global race-neutral equations; predicted 2.03 L | Normal | S |
| 1948-07-27 | FEV1 measured/predicted | 85 | % | GLI Global race-neutral equations | Normal | S |
| 1948-07-27 | FEV1/FVC | 0.73 | {ratio} | >=0.7 | Normal | S |
| 1948-07-27 | Fractional concentration of exhaled nitric oxide | 21 | [ppb] | Above 50 ppb high; 25 to 50 intermediate (ATS) | Normal | S |
| 1948-07-27 | Maximum expiratory gas flow Respiratory system airway by Peak flow meter | 330 | L/min | 80 percent of her personal best of 340 L/min | Normal | S |
| 1948-07-27 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 12-15.5 g/dL | Normal | S |
| 1948-07-27 | Leukocytes [#/volume] in Blood by Automated count | 7.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1948-07-27 | Eosinophils [#/volume] in Blood by Automated count | 0.24 | 10*3/uL | 0-0.5 10*3/uL | Normal | S |
| 1948-07-27 | Platelets [#/volume] in Blood by Automated count | 255 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1948-07-27 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1948-07-27 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1948-07-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1943)/1.73 sq M | 62 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1948-07-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1948-03-09 | Body height | 163 | cm | S |
| 1948-03-09 | Body weight | 88 | kg | S |
| 1948-03-09 | Body mass index (BMI) [Ratio] | 33.1 | kg/m2 | S |
| 1948-03-09 | Systolic blood pressure | 152 | mm[Hg] | S |
| 1948-03-09 | Diastolic blood pressure | 88 | mm[Hg] | S |
| 1948-03-09 | Heart rate | 82 | /min | S |
| 1948-03-09 | Respiratory rate | 20 | /min | S |
| 1948-03-09 | Body temperature | 36.7 | Cel | S |
| 1948-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 1948-06-15 | Body height | 163 | cm | S |
| 1948-06-15 | Body weight | 87.2 | kg | S |
| 1948-06-15 | Body mass index (BMI) [Ratio] | 32.8 | kg/m2 | S |
| 1948-06-15 | Systolic blood pressure | 138 | mm[Hg] | S |
| 1948-06-15 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 1948-06-15 | Heart rate | 98 | /min | S |
| 1948-06-15 | Respiratory rate | 22 | /min | S |
| 1948-06-15 | Body temperature | 37.4 | Cel | S |
| 1948-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 94 | % | S |
| 1948-09-21 | Body height | 163 | cm | S |
| 1948-09-21 | Body weight | 86 | kg | S |
| 1948-09-21 | Body mass index (BMI) [Ratio] | 32.4 | kg/m2 | S |
| 1948-09-21 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1948-09-21 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1948-09-21 | Heart rate | 70 | /min | S |
| 1948-09-21 | Respiratory rate | 16 | /min | S |
| 1948-09-21 | Body temperature | 36.6 | Cel | S |
| 1948-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1948-03-23 | Body height | 163 | cm | S |
| 1948-03-23 | Body weight | 87.6 | kg | S |
| 1948-03-23 | Body mass index (BMI) [Ratio] | 33 | kg/m2 | S |
| 1948-03-23 | Systolic blood pressure | 146 | mm[Hg] | S |
| 1948-03-23 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 1948-03-23 | Heart rate | 78 | /min | S |
| 1948-03-23 | Respiratory rate | 18 | /min | S |
| 1948-03-23 | Body temperature | 36.6 | Cel | S |
| 1948-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1948-05-04 | Body height | 163 | cm | S |
| 1948-05-04 | Body weight | 87 | kg | S |
| 1948-05-04 | Body mass index (BMI) [Ratio] | 32.7 | kg/m2 | S |
| 1948-05-04 | Systolic blood pressure | 134 | mm[Hg] | S |
| 1948-05-04 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1948-05-04 | Heart rate | 76 | /min | S |
| 1948-05-04 | Respiratory rate | 16 | /min | S |
| 1948-05-04 | Body temperature | 36.6 | Cel | S |
| 1948-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1948-07-27 | Body height | 163 | cm | S |
| 1948-07-27 | Body weight | 86.4 | kg | S |
| 1948-07-27 | Body mass index (BMI) [Ratio] | 32.5 | kg/m2 | S |
| 1948-07-27 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1948-07-27 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1948-07-27 | Heart rate | 72 | /min | S |
| 1948-07-27 | Respiratory rate | 16 | /min | S |
| 1948-07-27 | Body temperature | 36.5 | Cel | S |
| 1948-07-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1948-03-09 | New patient visit for four months of wheeze, night cough and breathlessness on exertion in a 72-year-old woman with long-standing asthma that was never confirmed: examination, chest X-ray, ECG, blood tests and BNP, and planning of lung function testing and an echocardiogram | finished | S |
| 1948-03-23 | Diagnosis visit: spirometry, FeNO and echocardiogram results with the pulmonology consultation; asthma confirmed, heart failure excluded, hypertensive heart disease found; start of budesonide-formoterol as maintenance and reliever | finished | S |
| 1948-05-04 | Six-week asthma review: control, inhaler technique and adherence, the ear, nose and throat result, blood pressure and reflux | finished | S |
| 1948-07-27 | Review six weeks after an exacerbation: control, repeat spirometry and FeNO, biologic assessment, blood pressure and the post-exacerbation plan | finished | S |
| 1948-06-15 | Same-day sick visit for an asthma exacerbation with a cold | finished | S |
| 1948-09-21 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Pulmonology consultation in two weeks with spirometry before and after bronchodilator, DLCO and FeNO, to confirm or refute asthma, separate it from COPD and heart disease, and plan treatment | completed | GL-GINA-2025, GL-NAEPP-2020, GL-CMID-2026 | S |
| Work-up of wheeze and breathlessness: chest X-ray, ECG, blood count with eosinophils, BNP, TSH and kidney function today; transthoracic echocardiogram before the consultation; albuterol continued as needed until testing, holding it for six hours before spirometry | completed | GL-GINA-2025, GL-NAEPP-2020, GL-AHA-HF-2022 | S |
| Home blood pressure readings twice daily for a week, with a validated upper-arm cuff, because clinic readings are raised | completed | GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Equity safeguards: spirometry read with race-neutral GLI Global equations, plain explanation of every result, and a check at each visit that her symptoms are not put down to her weight or age | completed | GL-ATS-RACE-2023, GL-MMWR-ASTHMA-2021 | S |
| GINA track 1: budesonide-formoterol 160/4.5 mcg as maintenance and reliever (one inhalation twice daily and one as needed, no more than 12 a day), albuterol stopped; inhaler technique, adherence and Asthma Control Test at every visit; a written asthma action plan with peak flow zones; review six weeks after any change and within a week of any exacerbation | completed | GL-GINA-2025, GL-NAEPP-2020, GL-CMID-2026 | S |
| Hypertensive heart disease without heart failure: amlodipine 5 mg daily (a beta-blocker avoided because of asthma), a lower-salt diet, home readings, and kidney function and potassium at follow-up | completed | GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Cardiovascular prevention: atorvastatin 20 mg daily for a 10-year ASCVD risk above 20 percent | completed | GL-AHA-HTN-2025 | S |
| Upper airway and reflux: fluticasone nasal spray and saline rinses, ear, nose and throat review with nasal endoscopy; omeprazole for eight weeks for heartburn with meal timing and head-of-bed elevation, then stop if settled | completed | GL-GINA-2025, GL-CMID-2026 | S |
| Weight and fitness, as she chooses: a dietitian visit, a walking plan she can follow on campus and in Washington, and a later discussion of medicines for weight if she wants one | completed | GL-GINA-2025, GL-CMID-2026 | S |
| Biologic assessment: not indicated while asthma is controlled on low-to-medium dose ICS-formoterol with good technique; repeat blood eosinophils and refer for biologic therapy if asthma becomes uncontrolled on step 4 to 5 treatment or there are two or more exacerbations needing oral corticosteroids in a year | completed | GL-GINA-2025, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| A confirmed diagnosis within three weeks: spirometry with bronchodilator response, FeNO and an echocardiogram, with the pulmonology consultation | 1948-03-23 | completed | Asthma confirmed by a 21 percent, 270 mL bronchodilator response and FeNO 46 ppb; heart failure excluded; hypertensive heart disease found, two weeks after the first visit | S |
| Asthma Control Test 20 or more, no night waking, and travel to Washington without breathlessness | 1948-07-27 | completed | Asthma Control Test 22; no night waking; travelled to two board meetings | S |
| Correct inhaler technique with her own inhaler at every visit, and a written asthma action plan she can use | 1948-05-04 | completed | Technique corrected with a spacer at six weeks; action plan written at diagnosis and used during the exacerbation | S |
| Blood pressure below 130/80 at home and in clinic | 1948-07-27 | completed | Clinic 128/78; home average 126/76 on amlodipine | S |
| No exacerbation needing oral corticosteroids | 1948-07-27 | completed | Not achieved: one moderate exacerbation with a cold, treated with five days of prednisone without admission | S |